Overview
- Legal name
- ZATA PHARMACEUTICALS, INC.
- Also known as
- ZATA PHARMACEUTICALS INC
- Registered location
- WORCESTER, MA, USA
- Website
- Company website ↗
- Primary NAICS
- 621511 — Medical Laboratories
- Latest award activity
- Aug 25, 2026
Read company summary
ZATA PHARMACEUTICALS, INC. is associated with UEI LM1CSJF7LLS6 and CAGE 62U84 in public federal records. AcornBids currently links 1 prime award totaling $6.7M in obligations to this entity. Its largest recorded federal customer by obligations is Department of Health and Human Services. Its recorded federal awards include work classified as All Other Professional, Scientific, and Technical Services. These categories describe the loaded award records, not a complete list of company capabilities. Its primary SAM.gov NAICS is 621511 (Medical Laboratories). Its public SAM.gov registration lists WORCESTER, MA, USA.
At a glance
Prime contract obligations across loaded award records. Obligations are not revenue or contract ceilings. Summary updated Oct 4, 2026. Refresh pending; these totals may be out of date.
Business information
Public SAM.gov registration details.
- Legal name
- ZATA PHARMACEUTICALS, INC.
- Doing business as
- ZATA PHARMACEUTICALS INC
- UEI
- LM1CSJF7LLS6
- CAGE
- 62U84
- Registered address
- 60 PRESCOTT ST, WORCESTER, MA, 01605, USA
- Registration status
- Active
- Primary NAICS
- 621511 — Medical Laboratories
- SAM activation
- Apr 2, 2026
- Initial registration
- Jul 16, 2010
- Entity start
- May 13, 2009
- SAM updated
- Apr 2, 2026
- Registration expires
- Mar 31, 2027
- Fiscal year end
- Dec 31
- Place of incorporation
- MA, USA
Research brief
Source facts
- Loaded prime-award records link 1 awards and $6,692,768 in reported obligations to this legal entity. Source
- Recorded awards include All Other Professional, Scientific, and Technical Services (NAICS 541990); this classification is not proof of every company capability. Source
- An example award describes: DEVELOPMENT AND MAINTENANCE OF FDA-ARGOS 2 UNIVERSAL CLOSED SYSTEMS FOR PATHOGEN REDUCTION IN DONATED WHOLE BLOOD UNITS Source
Federal award analysis
Net transaction obligations by federal fiscal period.
Reported transaction obligations by federal fiscal period; includes deobligations. Missing transactions are not estimated. Coverage: 1 of 1 selected awards. Select a period to explore its awards.
Funding change
Dated, valued transaction obligations in equal-length adjacent periods; missing records are unknown. Default: last completed federal fiscal year. Percentage is unavailable when the prior period has no positive reported obligations.
| Measure | Reported value |
|---|---|
| Current period | Oct 1, 2025 – Sep 30, 2026 |
| Current obligations | $-5.9M |
| Prior period | Oct 1, 2024 – Sep 30, 2025 |
| Prior obligations | Not reported |
| Change | Not reported |
| Growth | Not comparable |
Where the work is performed
State tile map; darker tiles have larger absolute net obligations. Outlined tiles indicate net deobligations. Unshaded tiles have no reported transactions in this selection. Other locations appear in the table.
Agencies
| Category | Period obligations | Awards |
|---|---|---|
| Department of Health and Human Services | $6.7M | 1 |
Offices
| Category | Period obligations | Awards |
|---|---|---|
| FDA OFFICE OF ACQ GRANT SVCS | $6.7M | 1 |
Naics
| Category | Period obligations | Awards |
|---|---|---|
| 541990 — All Other Professional, Scientific, and Technical Services | $6.7M | 1 |
Psc
| Category | Period obligations | Awards |
|---|---|---|
| AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH | $6.7M | 1 |
Vehicles
| Category | Period obligations | Awards |
|---|---|---|
| Unclassified | $6.7M | 1 |
States
| Category | Period obligations | Awards |
|---|---|---|
| MD | $6.7M | 1 |
Set Asides
| Category | Period obligations | Awards |
|---|---|---|
| NO SET ASIDE USED. | $6.7M | 1 |
Recent federal awards
Prime contract awards. Select an award to review its history and source evidence.
| Award / description | Awarding agency | Obligations | Start date | End date |
|---|---|---|---|---|
| 75F40121C00194DEVELOPMENT AND MAINTENANCE OF FDA-ARGOS 2 UNIVERSAL CLOSED SYSTEMS FOR PATHOGEN REDUCTION IN DONATED WHOLE BLOOD UNITS | Department of Health and Human Services | $6.7M | Sep 27, 2021 | Sep 26, 2023 |
Registration, certifications & contacts
| Registration evidence | Date |
|---|---|
| SAM updated | Apr 2, 2026 |
| Source loaded | Sep 26, 2026 |
| Initial registration | Jul 16, 2010 |
| Entity start | May 13, 2009 |
Registration classifications: Self Certified Small Disadvantaged Business, Small Business. These are separate from the reported certificates above.
| Industry | Reported size status |
|---|---|
| 621511 — Medical Laboratories | Not reported |
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| DAVID TABATADZE | Government business | Contact method not published | SAM registration | Not available |
| DAVID TABATADZE | Electronic business | Contact method not published | SAM registration | Not available |
Registered industries
- 621511 — Medical Laboratories
Registration classifications and published certificates do not by themselves establish eligibility for a particular solicitation. View SAM source
Related companies worth researching
Explore the customer, work and award-size evidence behind each match.
Data coverage and methodology
Sources: SAM.gov registration, USAspending awards and transactions, and linked supporting records. Prime contract obligations, IDV ceilings and assistance amounts are kept separate. Missing records are not zero activity. Company claims are labeled separately. Recompete signals are rule-based scores out of 100. Positioning windows are AcornBids estimates.
Disclosed relationships only. Missing records do not establish that a contractor has no partners. Ambiguous parent award identifiers are excluded.
Recently viewed companies
Keep your research moving
Save this company, track changes, and evaluate upcoming work against your targets.
Save to my research Find my fit